12
Sep

Eli Lilly’s Cyramza (ramucirumab) met its primary endpoint in a study on metastatic colorectal cancer, good news for a key cog in the drugmaker’s plans to capitalize on oncology.

…read more

Source: Cyramza, key to Lilly’s oncology hopes, comes through in colorectal cancer

    

0 No comments